[18F]PI-2620 Phase 3 Histopathological Study

An Open-label, Non-randomized, Multi-center Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of PET Imaging With [18F]PI-2620 for the Detection of Tau Deposition When Compared to Post-mortem Histopathology (ADvance)

This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.

Study Overview

• Status: Recruiting
• Conditions: Alzheimer Disease
• Intervention / Treatment: Drug: [18F]PI-2620

• Study Type: Interventional
• Enrollment (Estimated): 200
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Audrey Perrotin, PhD; Phone Number: +49 (0)30 461 1246 03; Email: clinicaltrials@life-mi.com
• Study Contact Backup: Name: Aleksandar Jovalekic, PhD; Phone Number: +49 (0)30 461 1246 03; Email: clinicaltrials@life-mi.com

Study Locations

• United States
  • Arizona
    • Phoenix, Arizona, United States, 85013
      • Recruiting
      • Barrow Neurological Institute
    • Sun City, Arizona, United States, 85352
      • Recruiting
      • Banner Sun Health Research Institute
  • California
    • Los Angeles, California, United States, 90095 - 7370
      • Recruiting
      • UC Los Angeles
    • Murrieta, California, United States, 92562
      • Recruiting
      • Esperanza Clinical
    • San Francisco, California, United States, 94114
      • Recruiting
      • Sutter Health
  • Florida
    • Hialeah, Florida, United States, 33016
      • Recruiting
      • Galiz Research
    • Jacksonville, Florida, United States, 32209
      • Withdrawn
      • UF College of Medicine - Jacksonville
    • Lady Lake, Florida, United States, 32159
      • Recruiting
      • K2 Medical Research
    • Maitland, Florida, United States, 32751
      • Recruiting
      • K2 Medical Research
    • Melbourne, Florida, United States, 32940
      • Recruiting
      • ClinCloud Research
    • Miami, Florida, United States, 33137
      • Recruiting
      • Miami Jewish Health Systems
    • Sarasota, Florida, United States, 34243
      • Terminated
      • The Roskamp Institute
    • Winter Park, Florida, United States, 32792
      • Recruiting
      • Charter Research
  • Massachusetts
    • Braintree, Massachusetts, United States, 02184
      • Recruiting
      • Alzheimer's Disease Center
    • Plymouth, Massachusetts, United States, 02360
      • Withdrawn
      • Headlands Research
  • Nebraska
    • Lincoln, Nebraska, United States, 68616
      • Withdrawn
      • Be Well Clinical Studies
  • New Hampshire
    • Lebanon, New Hampshire, United States, 07366
      • Recruiting
      • Darthmouth-Hitchcock Medical Center
  • New York
    • East Syracuse, New York, United States, 13057
      • Recruiting
      • Velocity Clinical Research
    • Syracuse, New York, United States, 13219
      • Recruiting
      • Ichor Research
  • North Carolina
    • Charlotte, North Carolina, United States, 28273
      • Terminated
      • American Carolina Clinical Research LLC
  • Ohio
    • Beachwood, Ohio, United States, 44131
      • Recruiting
      • Insight Clinical Trials LLC
    • Centerville, Ohio, United States, 45459
      • Recruiting
      • Valley Medical Research
  • Texas
    • Dallas, Texas, United States, 75231
      • Recruiting
      • Baylor Research Institute
    • Kerrville, Texas, United States, 78028
      • Recruiting
      • Sante Clinical Research
    • Round Rock, Texas, United States, 78681
      • Recruiting
      • Be Well Clinical Studies

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Only subjects who meet all of the following criteria will be eligible for enrollment into the study:

1. Males and females aged 50 years and over
2. Have a projected life expectancy of ≤ 1 year as determined by the investigator (terminal medical condition including but not limited to end-stage dementia, end-stage congestive heart failure, end-stage chronic obstructive pulmonary disease (COPD), or end-stage cancer)
3. Written informed consent obtained from the subject and/or the subject's legally authorized representative (LAR), as applicable, to consent for study procedures and brain donation (consent consistent with the legal requirements of the State in which the subject dies)
4. Can tolerate study procedures including lying down in PET scanner. The investigator will carefully assess each subject and use medical judgment to determine whether the subject can tolerate the imaging procedure

Exclusion Criteria:

Subjects will be excluded from the enrollment if they:

1. Are receiving aggressive treatment with life sustaining measures (e.g. receiving chemotherapy; palliative chemotherapy is allowed)
2. Are known to have a structural brain lesion that would interfere either with PET imaging or pathological assessment (e.g. lesions are typically > 2 cm at their greatest extent and may include stroke, primary or metastatic neoplasm, other tumors or cystic lesions. Subjects with a history of major stroke or traumatic brain injury or other structural lesion as well as cases with a history of primary Central Nervous System (CNS) neoplasm or known metastatic cancer must be discussed with the study sponsor prior to enrollment)
3. Have suspected encephalopathy due to alcoholism or end-stage liver disease
4. Are known to have a Glomerular Filtration Rate below < 15 mL/min
5. Have received an investigational or approved therapy directly targeting amyloid or tau
6. Are females of childbearing potential who are pregnant, lactating or breastfeeding, or who are not using adequate contraception
7. Have implants such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips and other medical implants that have not been certified for MRI, or history of claustrophobia in MRI (in case an MRI is planned to be performed)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PI-2620 PET Scan	Drug: [18F]PI-2620; The radioligand, [18F]PI-2620, will be injected intravenously at a dose of 185 MBq ± 20%

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Diagnostic Efficacy of the visual assessment of [18F]PI-2620 PET imaging, in correctly differentiating tau neurofibrillary pathology associated with AD (NFT Score of B0 or B1 = negative)	[18F]PI-2620 PET scans will be classified as either tau-positive or tau-negative as defined by the reading methodology by each of the 5 independent readers blinded to the clinical and pathology information. NFT scores (as defined in Hyman et al. 2012) will be used as pathology assessment SoT (standard of truth). Tau neurofibrillary pathology associated with AD is defined as either negative with NFT Scores of B0 or B1 or positive NFT Scores of B2 or B3. The [18F]PI-2620 PET visual assessment will be compared with the pathology assessment to derive sensitivity and specificity estimates for each individual reader. Sensitivity and specificity are percentages that can range from 0 to 100%. The primary endpoint is considered to be met if for the same 3 out of 5 readers, the lower bound of the 95% CIs for both sensitivity and specificity are ≥ 50%.	At autopsy, until study completion with an average of 1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Diagnostic Efficacy of the visual assessment of [18F]PI-2620 PET imaging, in correctly differentiating tau neurofibrillary pathology associated with AD (NFT Score of B0, B1 or B2 = negative)	[18F]PI-2620 PET scans will be classified as either tau-positive or tau-negative as defined by the reading methodology by each of the 5 independent readers blinded to the clinical and pathology information. NFT scores (as defined in Hyman et al. 2012) will be used as pathology assessment SoT (standard of truth). Tau neurofibrillary pathology associated with AD is defined as either negative with NFT Scores of B0, B1 or B2 or positive NFT Scores of B3. The [18F]PI-2620 PET visual assessment will be compared with the pathology assessment to derive sensitivity and specificity estimates for each individual reader. Sensitivity and specificity are percentages that can range from 0 to 100%. The primary endpoint is considered to be met if for the same 3 out of 5 readers, the lower bound of the 95% CIs for both sensitivity and specificity are ≥ 50%.	At autopsy, until study completion with an average of 1 year
Diagnostic efficacy of the visual assessment of [18F]PI-2620 PET imaging, in correctly differentiating levels of AD neuropathologic change (ADNC) ('No' or 'Low' levels of ADNC = negative)	[18F]PI-2620 PET scans will be classified as either tau-positive or tau-negative as defined by the reading methodology by each of the 5 independent readers blinded to the clinical and pathology information. ADNC levels according to NIA-AA criteria (Hyman et al., 2012) will be used as pathology assessment SoT (standard of truth). Level of ADNC according to NIA-AA criteria (considering Braak stage, Thal plaque score, and CERAD amyloid neuritic plaque score) is defined as either negative with 'no' or 'low' ADNC levels or positive with 'intermediate' or 'high' ADNC levels. The [18F]PI-2620 PET visual assessment will be compared with the pathology assessment to derive sensitivity and specificity estimates for each individual reader. Sensitivity and specificity are percentages that can range from 0 to 100%. The primary endpoint is considered to be met if for the same 3 out of 5 readers, the lower bound of the 95% CIs for both sensitivity and specificity are ≥ 50%.	At autopsy, until study completion with an average of 1 year
Diagnostic efficacy of the visual assessment of [18F]PI-2620 PET imaging, in correctly differentiating levels of ADNC ('No', 'Low' or 'Intermediate" levels of ADNC = negative)	[18F]PI-2620 PET scans will be classified as either tau-positive or tau-negative as defined by the reading methodology by each of the 5 independent readers blinded to the clinical and pathology information. ADNC levels according to NIA-AA criteria (Hyman et al., 2012) will be used as pathology assessment SoT (standard of truth). Level of ADNC according to NIA-AA criteria (considering Braak stage, Thal plaque score, and CERAD amyloid neuritic plaque score) is defined as either negative with 'no', 'low' or 'intermediate' ADNC levels or positive with 'high' ADNC levels. The [18F]PI-2620 PET visual assessment will be compared with the pathology assessment to derive sensitivity and specificity estimates for each individual reader. Sensitivity and specificity are percentages that can range from 0 to 100%. The primary endpoint is considered to be met if for the same 3 out of 5 readers, the lower bound of the 95% CIs for both sensitivity and specificity are ≥ 50%.	At autopsy, until study completion with an average of 1 year
Inter-reader agreement for the visual assessment of [18F]PI-2620 PET images	Fleiss kappa will be used to measure the inter-reader agreement for the visual assessment of [18F]PI-2620 PET images.	Baseline scan

Collaborators and Investigators

• Sponsor: Lantheus Biosciences Ltd.
• Investigators: Principal Investigator: Alireza Atri, MD, PhD, Banner Health; Study Director: Andrew Stephens, MD, PhD, Life Molecular Imaging

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2022
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): June 1, 2027

Study Registration Dates

• First Submitted: November 17, 2022
• First Submitted That Met QC Criteria: December 5, 2022
• First Posted (Actual): December 8, 2022

Study Record Updates

• Last Update Posted (Actual): May 22, 2026
• Last Update Submitted That Met QC Criteria: May 20, 2026
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Mental Disorders; Neurocognitive Disorders; Dementia; Tauopathies; Neurodegenerative Diseases; Alzheimer Disease; ((18)F)PI-2620
• Other Study ID Numbers: LMT-01-01-22

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No